欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 精品无码成人久久久久久 | 色综合桃花网 | 国产最新永久地址发布页 | 国产精品理论片在线观看日韩 | 久久久99精品免费观看 | 亚洲国产一区视频 | 欧美成人国产精美视频 | 中字幕视频在线永久在线 | 亚洲欧洲中文字幕日产无码 | 在线看片免费人成视频国产片 | 欧美自拍偷拍一区二区三区 | 久久精品亚洲热综合一本奇米 | 国产极品美女高潮无套在线观看 | 欧美一级在线不卡视频 | 影音先锋av在线资源网 | 日本乱人 | 国产高清又黄又爽又刺激视频 | 亚洲人成在线播放网站 | 欧美一级无片 | 成年美女黄网站色大片免费看 | 国产在线不卡视频免费视频 | 永久免费aⅴ无码网站国产 永久免费av | 一本大道东京热无码一区 | 国产日本韩国欧美 | 欧美自拍偷拍一区二区三区 | 亚洲伊人av二区 | 国产精品va无码一区二区 | 日本a在线天堂 | 不卡人妻精品久久字幕妓女网 | 日韩精品一区二区三区中文不卡 | 精品国产网红福利在线观看 | 97国产在线公开免 | 熟妇人妻中文字幕 | 亚洲视频国产视频 | 日韩高清性爽一级毛片免费 | 91麻豆国产福利精品 | 日韩一区二区三区在线成人 | 97人洗澡人人澡人人爽人人模 | 午夜看片a福利在线 | 国产成人精品一区二 | 国产精品一区二区在线观看免费 |